Connect with us

Cannabis News

White House Drug Strategy Shows Trump Administration’s Conflicts On Marijuana And Other Issues, Experts Say

Published

on

“On the one hand, the administration is moving in the direction of liberalizing access to cannabis, but at the same time, in the strategy, it talks about the risks of doing so.”

The White House’s newly released strategy to combat the nation’s drug and addiction crisis calls for some ambitious public health approaches that some experts say are laudable but will be hindered by the administration’s actions.

195 wide pages National Strategy for Drug Controlpublished on May 4, advocates making access to treatment easier than obtaining drugs, preventing young people from developing addictions in the first place, increasing support for people in recovery and reducing overdose deaths.

These broad goals are widely supported by public health researchers, addiction treatment clinicians, and recovery advocates.

But meeting such goals will be difficult for the administration mass layoffs of federal workers, cancel the investigation and community grants, attacks on institutions and practices which are useful for people who use drugs, and Medicaid cutsa state-federal health insurance program that is the nation’s largest payer of addiction and mental health care for low-income people.

Many of the components of the National Drug Control Strategy are “things that we would agree to and fully support”. Libby Joneswho leads overdose prevention efforts at the Global Health Advocacy Incubator, a public health advocacy group.

But “there are disconnects in terms of what’s important to the strategy and then what they’re actually going to fund,” he said of the Trump administration. “These inconsistencies are felt particularly loudly in this strategy.”

The White House’s National Drug Control Strategy has been released every two yearsit is a document that aims to define a coordinated approach to the federal government that has been one of the country’s defining issues in recent decades.

since 2000, More than 1.1 million people they have died of drug overdoses. Despite the deaths has decreased recentlythe number continues to rise compared to previous decades, and research suggests Overdose death rates for black Americans and Native Americans are disproportionately high.

The strategy document released this week is the first of President Donald Trump’s current term. In keeping with the administration’s approach to addiction issues, it places a strong emphasis on law enforcement efforts to reduce the supply of illegal drugs. The document repeatedly refers to a “war” against foreign “terrorist organizations” — the Trump administration’s term for drug cartels — and increased enforcement at US borders.

Also determines plans implementing artificial intelligence technologies to analyze illegal drugs brought into the country and wastewater testing to detect illegal drug use nationwide.

The second half of the strategy focuses on reducing the demand for drugs, supporting public health prevention efforts, addiction treatment, and helping people in recovery. Religion promotes the role of recovery and the widespread use of overdose reversal drugs such as naloxone.

In a news release, the White House Office of National Drug Control Policy called the document a “road map” that will “continue to dismantle our nation’s drug supply and defeat the scourge of illegal drugs.”

The Trump administration did not respond to requests for comment on how the strategy fits with its other actions.

In December, Trump signed one Reauthorization of the HELP Actcontinues with various treatment and recovery-related subsidies and the requirement that Medicaid cover all FDA-approved medications for opioid use disorders. He announced in January The Great American Recovery Initiativeincluding a 100 million dollar investment to combat homelessness, opioid addiction and public safety.

However, few details have been released about the initiative, and in January, about a month after the HELP Act was passed, billions of dollars in addiction-related grants suddenly became available. finish and reset In a frantic 24-hour period.

This “whirlwind” left a “sense of instability and uncertainty in the area”. Yngvild OlsenNational consultant for Manatt Health consulting. He led substance use treatment policy at the Substance Abuse and Mental Health Services Administration, or SAMHSA, under the Biden administration and left about six months into Trump’s second term.

Insecurity increased the president’s 2027 budget requestwhich proposes cutting various addiction and mental health programs and consolidating key federal agencies that work on these issues. Jones’ team and about 100 others in the field have done it he signed a letter Asking Congress to reject the proposals, as they did with similar requests last year.

The national drug strategy adds new and contradictory information to this confusing landscape.

Increasing access to treatment

One of the most significant public health goals in the strategy, mentioned at least half a dozen times, is to make treatment easier than buying illegal drugs.

National data underscores the need for: more than 80% of Americans those who need substance use treatment do not receive it.

The administration’s actions regarding health insurance may make it difficult to improve this statistic.

It’s Medicaid primary source of health coverage for adults with opioid use disorder. When implemented, the Medicaid work requirement in Trump’s One Big Beautiful Bill Act is expected to eliminate that coverage. About 1.6 million people with substance use disorders.

The last time the Medicaid rolls were purged was after that covid-era protections have expired – Many people who were receiving drugs for opioid addiction stopped and fewer people started treatment, according to one. research published last year.

Olsen, who is also an addiction medicine doctor, said she loves the strategy’s focus on making treatment readily available to anyone who wants it. But he said that’s “hard to really imagine when people might have to pay for it themselves because they might lose their Medicaid insurance coverage.”

Appreciate an analysis The upcoming Medicaid changes could cause 156,000 people to lose access to opioid use disorder medication and cause 1,000 more fatal overdoses a year.

People with private insurance may also be affected.

The Trump administration has he refused to enforce it Addressing the regulations of the Biden era strengthening mental health paritythe idea that insurance should cover mental illness and addiction treatment in comparison to physical treatments. And recently, the administration said that redo those regulations in total, raising fears that addiction treatment may become increasingly affordable.

The administration did not respond to specific questions about how it reconciles Medicaid and equity action with the goal of increasing treatment.

Prioritizing prevention

The strategy highlights that preventing addictions before they start is one of the keys to reducing drug demand. It calls for “promoting a drug-free America as the social norm” and implementing science-backed school and community-based programs.

“Investing in early prevention, before drug use starts, saves lives and resources,” he says, citing. several studies about cost effectiveness among such programs.

However, the president’s budget proposes cuts to these types of programs, and federal layoffs have decimated the agencies that would implement this work.

of the White House final quote request He proposes to cut approximately $220 million from SAMHSA Center for Substance Abuse Prevention and almost 40 million dollars Drug-free communities the program

Since the new administration began, SAMHSA has lost about half of the workforceand the Centers for Disease Control and Prevention about a quarter.

“It’s not clear to me that they’re going to have the funds or the people to make it happen,” Olsen said of the strategy’s prevention goals.

The strategy presents another wrinkle in the marijuana debate. The document points to marijuana use as one of the drivers of drug use disorders and “convergent evidence from multiple sources” suggests that cannabis use increases the risk of psychosis. It requires the development of new tools to treat marijuana withdrawal and addiction.

However, just two weeks ago, the White House led to reclassification medical marijuana is moving to and from a lower level of scheduled substances audition to do the same with marijuana.

“The administration, on the one hand, is moving in the direction of liberalizing access to cannabis,” Jones said, “but at the same time, strategically, it’s talking about the dangers of doing that.”

“There’s a disconnect there that begs the question: who do you think you are?” he added.

The administration did not respond to specific questions about its marijuana policies.

Stopping overdose deaths

One of the most surprising elements of the National Drug Control Strategy comes in the last paragraph of the last chapter. It focuses on public drug testing programs, which often use test strips to help people who use drugs determine whether their purchased lot contains more dangerous substances, such as fentanyl or xylazine. This helps them determine whether or not to use these drugs safely.

“Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legalized,” the strategy document says.

However, SAMHSA announced a last letter He said he would no longer pay for the test strips as part of the Trump administration’s “harm reduction and move away from practices that facilitate illegal drug use.”

The administration has also attacked harm reduction programs executive order and his the budget requests. He did not respond to specific questions about how that position affects the drug control strategy.

Regina LaBelleThe Georgetown University professor, who served as acting director of the Office of National Drug Control Policy in the Biden administration, wrote about the contradiction. a blog post: “It is the height of rhetoric over reality to defend an instrument while at the same time cutting off the funding used to acquire it.”

KFF Health News It is a national newsroom that produces in-depth journalism on health issues and is one of the core program drivers of KFF, an independent source of health policy research, surveys and journalism. Learn more KFF.

This the article appeared for the first time KFF Health News and is republished here under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Massachusetts CCC pauses license applications

Published

on

By











The Cannabis Control Commission, the government body that oversees the marijuana business in the state of Massachusetts (USA), has decided to temporarily stop accepting new license applications for growing marijuana, both indoors and outdoors. This hiatus officially began on June 16, 2026.

Anyone planning to apply for a new marijuana cultivation license after June 16, 2026 will not be able to do so while this suspension is in effect. The Commission will not accept such requests during this period.

There are two groups that can continue normally. First, anyone who submitted an application before June 16, 2026, will continue to review and process applications as usual. Second, applicants for specific programs designed to help communities historically affected by drug laws, known as the Social Equity Program and the Economic Empowerment Program, are exempt from this suspension if they apply for a smaller-scale “Microenterprise” license.

The suspension will be in effect for 120 days from June 16, 2026, which is currently scheduled to be lifted around mid-October 2026. However, the Commission has the power to terminate earlier or extend further, depending on market conditions.

Source: Massachusetts Cannabis Control Commission










Continue Reading

Cannabis News

Federal Marijuana Rescheduling ‘Does Not Appear To Apply’ To Washington Businesses, State Officials Say

Published

on

By

Marijuana regulators in Washington say the Trump administration’s move to re-regulate cannabis at the federal level “doesn’t appear to apply” to the state’s businesses.

US Department of Justice in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA). A trial scheduled for this month will take place consider marijuana III.

“Washington does not issue licenses to producers, processors or retailers of medical cannabis,” the state’s Liquor and Cannabis Board (LCB) said in guidelines released Tuesday. “Instead, Washington has a single recreational market and within that market producers/processors can manufacture (DOH) compliant products, and certain retailers can sell DOH-compliant products to adult patients and all designated providers.”

“Therefore, Washington cannabis licensees do not appear to qualify as ‘state medical marijuana licensees’ and therefore may not be eligible for registration under the final Rule,” the agency said, referring to the Drug Enforcement Administration (DEA). Registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

That said, the LCB “does not take a position if licensees decide to apply for federal registration,” the guidance continues. “If a licensee is seeking federal registration, we would be interested in learning about their experience and federal decisions.”

However, “based on our analysis, the federal reorganization in its current form does not appear to apply to cannabis licensees in Washington, primarily because of the legal framework governing recreational cannabis,” the LCB said.

The agency emphasized, however, that while it has consulted with the Cannabis Regulatory Association, the National Governors Association and industry stakeholders, its current opinion does not represent Washington’s formal opinion and “may not be our final interpretation as information is evolving and the decision may not rest with the state.”

“We await additional guidance from the federal agencies involved, new or updated federal agency processes and/or other federal procedures,” he said. he saidreferring to the next administrative hearing and Ongoing litigation calls into question the rescheduling of cannabis.

“The LCB recognizes that there are many cannabis growers, processors, and retailers actively involved in the production and sale of medical cannabis in Washington. These businesses may or may not be eligible to use the 280e tax deduction, and may also register with the DEA III. Ultimately, they have no input into whether their licensees meet the criteria for “state medical marijuana licensees,” as that determination can be made unilaterally by the DOJ within the meaning of the Final Rule. to reasonably interpret and determine that Washington cannabis licensees qualify as “state medical marijuana licensees.”

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

In California, regulators recently approved emergency rule changes to the state’s marijuana licensing process. to make it easier for companies to receive benefits In line with the Trump administration’s latest move to federally regulate medical cannabis.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

How New Zealand showed up in London’s cannabis industry

Published

on

By

The medical cannabis market is expected to grow from $47 billion to $149 billion by 2031, and New Zealand has a real role to play in that story. And thanks in large part to New Zealand Trade and Enterprise (NZTE), the government’s international business development agency, Puro is starting to play.

At Cannabis Europa 2026 London, NZTE hosted an evening event at the City Arts Bar with Puro, New Zealand companies Bluelab, Rua Bioscience and CannFX. Puro called it The NZ Room.

Beyond all things Kiwiana – including Puro brand kiwifruit, Kiwi’d – the room was filled with some pretty amazing people: Ivy League scientists, company founders, patients, advocates, industry players, government officials, Maori tribal leaders and a tough Scotsman. All in the same space with the same true passion for where this industry is going.

It was one of those rooms where conversations went well when they had to end. That’s usually a sign of something well done.

Made possible by NZTE
For Puro, the NZTE relationship has been formative. With ongoing support, Puro has entered the Australian market with 47 unique product SKUs and signed a £7 million supply agreement with UK distributor IPS Pharma.

NZTE understands the potential of the New Zealand cannabis industry. The willingness to support this nascent industry and put New Zealand in the spotlight at events like Cannabis Europa is very significant. New Zealand is a small country and the country’s credibility in international markets is built from relationship to relationship, room by room. NZTE helps build those rooms.

© Cigar

what’s next
For the first time, patients in the UK have access to medicinal cannabis grown in New Zealand. That’s the direct result of years of work by Puro’s team, but it’s not worth much if you can’t connect with buyers globally. Creating international relationships that events like Cannabis Europa make this possible.

“We are grateful for the extensive support from the New Zealand Government that drives our progress, including the Ministry of Primary Industries’ support for our genetic breeding, product innovation and market access goals. This collective effort from agencies such as the Ministry of Business, Innovation and Employment, NZTE and the New Zealand Export Credit Bureau ensures that Mail that started in London will continue to grow in Puro’s international goals,” he said. a statement

For more information:
clean
www.puro.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media